Sign Up to like & get
recommendations!
0
Published in 2017 at "Nature Communications"
DOI: 10.1038/ncomms14060
Abstract: Somatic mutations in spliceosome genes are detectable in ∼50% of patients with myelodysplastic syndromes (MDS). We hypothesize that cells harbouring spliceosome gene mutations have increased sensitivity to pharmacological perturbation of the spliceosome. We focus on…
read more here.
Keywords:
u2af1 expressing;
mutant u2af1;
expressing cells;
u2af1 s34f ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Clinical and Experimental Pharmacology and Physiology"
DOI: 10.1111/1440-1681.13646
Abstract: The recurrent mutation (S34F) in splicing factor U2AF1 is frequently observed in lung adenocarcinoma, but its function remains largely unknown. To determine the mechanistic basis and consequences of U2AF1 mutations, we established non–small cell lung…
read more here.
Keywords:
u2af1 s34f;
damage;
dna damage;
lung ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Cancer research"
DOI: 10.1158/0008-5472.can-17-3970
Abstract: Heterozygous somatic mutations in spliceosome genes (U2AF1, SF3B1, ZRSR2, or SRSF2) occur in >50% of patients with myelodysplastic syndrome (MDS). These mutations occur early in disease development, suggesting that they contribute to MDS pathogenesis and…
read more here.
Keywords:
loop associated;
atr;
dna;
u2af1 s34f ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "PLoS Biology"
DOI: 10.1371/journal.pbio.3000920
Abstract: U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1) forms a heterodimeric complex with U2AF2 that is primarily responsible for 3ʹ splice site selection. U2AF1 mutations have been identified in most cancers but are prevalent in…
read more here.
Keywords:
u2af1 s34f;
s34f mutation;
mutation;
ribosome biogenesis ... See more keywords